UBS Group
CMPX icon

UBS Group’s Compass Therapeutics CMPX Stock Holding History

UBS Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.7M Buy
2,391,333
+2,223,477
+1,325% +$12.8M ﹤0.01% 3096
2025
Q4 		$901K Sell
167,856
-30,415
-15% -$140K ﹤0.01% 5663
2025
Q3 		$694K Sell
198,271
-65,255
-25% -$206K ﹤0.01% 5849
2025
Q2 		$685K Buy
263,526
+110,675
+72% +$228K ﹤0.01% 5753
2025
Q1 		$290K Sell
152,851
-10,805
-7% -$28.7K ﹤0.01% 6274
2024
Q4 		$237K Buy
163,656
+98,256
+150% +$163K ﹤0.01% 6350
2024
Q3 		$120K Buy
65,400
+15,172
+30% +$18.9K ﹤0.01% 6230
2024
Q2 		$50.2K Sell
50,228
-59,983
-54% -$87.6K ﹤0.01% 6686
2024
Q1 		$218K Buy
110,211
+7,663
+7% +$13.2K ﹤0.01% 5800
2023
Q4 		$160K Buy
102,548
+43,503
+74% +$75.3K ﹤0.01% 5907
2023
Q3 		$116K Sell
59,045
-3,417
-5% -$8.45K ﹤0.01% 5734
2023
Q2 		$199K Buy
62,462
+54,780
+713% +$172K ﹤0.01% 5482
2023
Q1 		$25.1K Sell
7,682
-4,137
-35% -$16.2K ﹤0.01% 6913
2022
Q4 		$59.5K Buy
11,819
+4,591
+64% +$18.3K ﹤0.01% 6593
2022
Q3 		$16K Hold
7,228
– – ﹤0.01% 7677
2022
Q2 		$19K Hold
7,228
– – ﹤0.01% 6933
2022
Q1 		$10K Hold
7,228
– – ﹤0.01% 8399
2021
Q4 		$23K Buy
+7,228
New +$24K ﹤0.01% 7672

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's CMPX Position: Q1 2026 in Review

UBS Group increased its Compass Therapeutics (CMPX) stake by 1,325% in Q1 2026, buying an estimated $12.8M and bringing the position to 2,391,333 shares worth $12.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3096.

UBS Group first reported a position in CMPX in Q4 2021 and has held it in 18 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • UBS Group held 2,391,333 shares of Compass Therapeutics worth $12.7M as of Q1 2026.
  • UBS Group bought 2,223,477 Compass Therapeutics shares in Q1 2026, an estimated $12.8M.
  • Compass Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3096 holding.
  • UBS Group first reported a position in Compass Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.